Table 1. IVW meta-analysis of MR estimates of IL6R blockade for UK Biobank and COVID-19 HGI outcomes.
| OR (95% CI) | P value | Cases / controls | |
|---|---|---|---|
| Sepsis | |||
| Sepsis (all admissions) | 0.8 (0.66–0.96) | 0.019 | 11,643 / 474,841 |
| Sepsis (28-day death) | 0.74 (0.47–1.15) | 0.180 | 1,896 / 484,588 |
| Sepsis (critical care) | 0.48 (0.3–0.78) | 0.003 | 1,380 / 429,985 |
| Sepsis (28-day death in critical care) | 0.37 (0.14–0.98) | 0.046 | 347 / 431,018 |
| COVID-19 | |||
| COVID-19 (All cases vs. population) | 0.93 (0.89–0.98) | 0.009 | 159,840 / 2,782,977 |
| COVID-19 (Hospitalised) | 0.83 (0.74–0.93) | 0.002 | 44,986 / 2,356,386 |
| COVID-19 (Severe respiratory vs. population) | 0.69 (0.57–0.84) | <0.001 | 18,152 / 1,145,546 |
| Infection | |||
| URTI | 1.67 (1.13–2.48) | 0.010 | 2,795 / 483,689 |
| Endocarditis | 1.66 (0.88–3.15) | 0.120 | 1,080 / 485,404 |
| Cholecystitis | 1.53 (1.12–2.08) | 0.007 | 4,052 / 482,432 |
| UTI | 1.32 (1.17–1.5) | <0.001 | 21,958 / 464,256 |
| Osteomyelitis | 1.27 (0.88–1.82) | 0.207 | 4,836 / 481,648 |
| Appendicitis | 1.21 (0.93–1.58) | 0.153 | 4,604 / 481,880 |
| Cellulitis | 1.2 (1.02–1.41) | 0.028 | 12,196 / 474,288 |
| LRTI | 1 (0.83–1.22) | 0.960 | 14,135 / 472,349 |
| Pneumonia | 0.97 (0.86–1.1) | 0.642 | 22,567 / 463,917 |
| Sepsis | 0.8 (0.66–0.96) | 0.019 | 11,643 / 474,841 |
| Other critical care outcomes | |||
| Pneumonia (critical care) | 0.69 (0.49–0.97) | 0.034 | 2,758 / 428,607 |
| LRTI (critical care) | 0.51 (0.23–1.12) | 0.095 | 585 / 430,780 |
| Pneumonia (28-day death in critical care) | 0.5 (0.23–1.08) | 0.077 | 803 / 430,820 |
CI, confidence interval; COVID-19, Coronavirus Disease 2019; HGI, Host Genetics Initiative; IVW, inverse variance weighted; LRTI, lower respiratory tract infection; MR, Mendelian randomisation; OR, odds ratio; URTI, upper respiratory tract infection; UTI, urinary tract infection.